Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | PHASE3 | COMPLETED | 160 | — | — | Apr 19, 2022 | Apr 14, 2026 | Apr 27, 2026 | 105 | United States, Australia +10 |
| Arm | Type | Description |
|---|---|---|
| Arm A: Sotorasib 960 mg QD + panitumumab | EXPERIMENTAL | - |
| Arm B: Sotorasib 240 mg QD + panitumumab | EXPERIMENTAL | - |
| Arm C : Investigator's choice | ACTIVE_COMPARATOR | Participants will be administered trifluridine and tipiracil, or regorafenib |
| Name | Type | Description |
|---|---|---|
| Sotorasib | DRUG | Sotorasib will be administered orally |
| Panitumumab | DRUG | Panitumumab will be administered as intravenous (IV) infusion |
| Trifluridine and Tipiracil | DRUG | Trifluridine and Tipiracil will be administered orally |
| Regorafenib | DRUG | Regorafenib will be administered orally |
Inclusion Criteria: * Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures. * Age ≥18 years. * Pathologically documented metastatic colorectal adenocarcinoma with Kirsten rat sarcoma (KRAS) p.G12C mutation as determined by prospective cent...